This is a group of rare genetic disorders. They cause unusual hives (a skin rash) that appear suddenly, often triggered by cold. These hives can be accompanied by other symptoms like fever, joint pain, and sometimes affect the brain or heart. The specific type depends on which gene is affected.
Every report comes from a Lived member, sent anonymously.
Have you tried Interleukin 1 Receptor Antagonist Protein for Cryopyrin-Associated Periodic Syndromes?
Cryopyrin-associated periodic syndromes (CAPS) are a rare inherited condition in which the body's built-in inflammation system switches on too easily and too strongly. The result is repeated bouts of inflammation without an infection behind them: a hive-like rash, fever or chills, aching joints and muscles, red eyes and deep tiredness. Episodes can last from a few hours to several days, and in some people symptoms are present almost all the time. CAPS is a spectrum rather than three separate diseases. Familial cold autoinflammatory syndrome (FCAS) is the mildest form, with flares set off mainly by cold. Muckle-Wells syndrome (MWS) sits in the middle and can lead to gradual hearing loss and kidney damage. Neonatal-onset multisystem inflammatory disease (NOMID, also called chronic infantile neurologic, cutaneous and articular syndrome, or CINCA) is the most severe form, starting at or soon after birth and affecting the brain, eyes, bones and joints. The rash can look like ordinary hives, but it is usually painful or burning rather than itchy, and in FCAS it tends to appear an hour or more after cold exposure, often on skin that was not directly chilled. CAPS matters because ongoing inflammation, left untreated, can permanently damage hearing, vision, the kidneys and the nervous system.
CAPS is caused by a change (variant) in a gene called NLRP3, which makes a protein called cryopyrin. Cryopyrin helps the immune system decide when to release interleukin-1 (IL-1), a chemical messenger that drives fever and inflammation. The variant leaves cryopyrin overactive, so IL-1 is released when it should not be. The condition usually follows an autosomal dominant pattern: one altered copy of the gene is enough, so a parent with CAPS has a 50% chance of passing it to each child. Some people have no family history because the variant arose new in them. Rarely, the change develops in only some of the body's cells after conception, which can produce milder or atypical symptoms that start in adulthood. The gene variant is the cause; cold, stress, infections, injury and lack of sleep are triggers that can set off an individual flare. Cold is a particularly strong trigger in FCAS, and flares may be more frequent in winter, on damp or windy days, or after air conditioning.
Diagnosis starts with the pattern: recurring rash and fever that began early in life, flares after cold, and sometimes relatives with early hearing loss or kidney failure. A symptom diary kept over weeks helps show that pattern. Because CAPS is rare and its features overlap with more common problems, diagnosis is often delayed, especially in the mild form, and many people with FCAS are not diagnosed until adulthood. Blood tests during a flare and between flares look for inflammation. C-reactive protein (CRP) and serum amyloid A (SAA) are proteins the liver releases when inflammation is active. In CAPS they are usually raised during symptoms and may stay raised between them. SAA matters in particular because persistently high levels feed the amyloid deposits that can damage the kidneys. Clinicians also rule out infections, immune deficiencies, autoimmune diseases and blood cancers that can cause recurring fevers. Genetic testing for NLRP3 variants confirms most cases, but a negative or unclear result does not rule CAPS out, particularly when the variant is present in only some cells. Specialists can make the diagnosis without genetic confirmation when inflammation markers are raised along with at least two characteristic features, such as the hive-like rash, cold-triggered episodes, hearing loss of the inner-ear type, joint or muscle symptoms, chronic meningitis or bone changes. Once CAPS is suspected, a baseline hearing test, an eye exam and, for moderate or severe forms, neurological assessment and sometimes a brain scan with magnetic resonance imaging (MRI) or a lumbar puncture (spinal tap) help measure how far it has reached.
There is no cure for CAPS, but treatment that blocks interleukin-1 controls it very effectively for most people. Because IL-1 drives the inflammation, blocking it can stop flares, bring inflammation markers back to normal and prevent further damage. Starting early matters: hearing loss may halt or partly recover with prompt treatment but can become permanent if treatment is delayed. Anti-IL-1 treatment is recommended across the whole spectrum, including the mild form. Three IL-1 blockers are available in the United States, all given as injections under the skin. Anakinra (Kineret) is a short-acting daily injection approved for NOMID; it reaches the brain and spinal fluid well, which is one reason it is often chosen when meningitis is present. Canakinumab (Ilaris) is an antibody injected every four to eight weeks and is approved for CAPS, including FCAS and MWS, in adults and children 4 years and older. Rilonacept (Arcalyst) is a weekly injection approved for FCAS and MWS from age 12. The choice depends on age, severity, how often someone is willing to inject and how well each option controls symptoms. Doses are adjusted to reach the lowest disease activity possible, and a few people, particularly those with unusual variants, respond only partly. The main trade-off is infection. By damping a key part of the immune response, these medicines raise the risk of serious infections, so clinicians check for tuberculosis and other infections before starting, update vaccinations first, and avoid live vaccines during treatment. Other care fills the gaps. Anti-inflammatory pain relievers can ease aches and fever, steroid eye drops and artificial tears help eye symptoms, and hearing aids, physical therapy and orthopedic devices address existing damage. In the mild form, keeping warm and protecting hands and wrists from cold can reduce flares.
With IL-1 blocking treatment, the outlook for CAPS has improved considerably. Many people go from frequent flares and constant fatigue to few or no symptoms, and the risk of kidney amyloidosis, which affects roughly 10% of untreated people with the mild form and 25% with the moderate form, is reduced when inflammation is kept down. Damage that happened before treatment, such as advanced hearing loss or bone deformity in NOMID, may not reverse. Treatment is usually lifelong, since stopping tends to bring flares back. Daily life involves a regular injection routine and paying attention to infections. Fatigue, irritability and the unpredictability of flares can affect school, work and social life, and CAPS has been linked with anxiety, depression and isolation, so psychological support and patient networks are part of care, not an extra. Follow-up with a rheumatologist or autoinflammatory specialist is regular and fairly thorough. It typically includes CRP and SAA blood tests, urine and kidney function tests to watch for amyloidosis, hearing tests, eye exams and, for children, growth checks. In severe forms, neurological reviews and imaging track the brain and bones. Because CAPS is inherited, genetic counseling can help families understand the chance of passing it on and whether relatives should be checked.
Arrange an evaluation, ideally with a rheumatologist, if you or your child has recurring episodes of rash with fever, joint pain or red eyes, especially when they follow cold exposure or began in infancy, or if relatives have had early hearing loss or kidney failure alongside similar symptoms. For someone already diagnosed, contact the care team when flares return or increase despite treatment, or when you notice new hearing difficulty, eye pain, redness or vision change, or persistent headaches, since these can signal inflammation reaching the ears, eyes or brain. While taking an IL-1 blocker, call the care team promptly about fever or signs of an infection, such as a cough, painful urination or a red, hot area of skin, so they can decide whether to pause treatment and what infection needs treating.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Cryopyrin-Associated Periodic Syndromes is like, what's helped you, or ask the community a question.